期刊文献+

小剂量肝素钠与低分子肝素钙对脓毒症治疗作用的对比研究 被引量:18

Clinical effects comparison of low dose heparin and low molecular weight heparin on sepsis
下载PDF
导出
摘要 目的观察小剂量肝素钠与低分子肝素钙对脓毒症的治疗效果差异。方法将90例脓毒症患者随机分为A、B、C三组,A组给予常规治疗包括早期广谱抗生素,液体复苏等,B组常规治疗基础上持续给予小剂量肝素5~10U/(kg·h)静脉泵入,C组在常规治疗基础上加低分子肝素钙0.6 ml皮下注射。对比三组患者治疗前及治疗后第1、3、5、7 d急性生理学慢性健康状况Ⅱ(APACHEⅡ)评分,治疗前和治疗后的凝血指标、炎症因子指标、播散性血管内凝血(DIC)发生率、28 d病死率和不良反应发生率。结果 B、C两组患者治疗后各时点APACHEⅡ显著低于A组(P〈0.05),C组患者治疗5 d后APACHEⅡ分值显著低于B组(P〈0.05)。B、C两组患者治疗后血小板(PLT)、纤维蛋白原(Fib)、凝血活酶时间(APTT),凝血酶原时间(PT)水平显著优于A组(P〈0.01),C组患者各指标显著优于B组(P〈0.05)。B、C两组患者治疗后血清肿瘤坏死因子(TNF-α)、白细胞介素-6(IL-6)、C反应蛋白(CRP)水平显著低于A组(P〈0.05),C组患者TNF-α水平显著低于B组(P〈0.05)。B、C两组患者DIC发生率、28 d病死率显著低于A组(P〈0.01,P〈0.05),C组患者DIC发生率显著低于B组(P〈0.05)。结论低分子肝素钙对脓毒症的治疗更为有效,可以有效改善患者的凝血功能及炎症水平,具有临床应用价值。 Objective To study the clinical effects difference of low dose heparin and low molecular weight heparin on sepsis. Methods A total of 90 sepsis patients were randomly divided into A,B,C three group,30 patients in each group. Patients in group A were treated by routine therapy including antibiotic treatment and fluid resuscitation. Patients in group B were treated by routine therapy and heparin 5 ~ 10 U / kg·h intravenous infusion. Patients in group C were treated by routine therapy and low molecular weight heparin 0. 6m L subcutaneous. The APACHE Ⅱ scores were compared between three groups before and on d1,d 3,d 5,and d 7 after treatment. The coagulation index,inflammation factor index,DIC rate and death rate in 28 d were compared. Results The APACHE Ⅱ score in group B and group C was significantly less than that in group A at different time after treatment( P〈0. 05). After treatment,APACHE Ⅱ score in group C was significantly less than that in group B on d 5( P〈0. 05). The PLT,Fib,APTT and PT levels in group B and group C were significantly better than those in group A( P〈0. 01). And those indexes in group C were significantly better than those in group B( P〈0. 05). The serum TNF- α,IL- 6,CRP levels in group B and group C were significantly lower than those in group A( P〈0. 05). And TNF- α level in group C was significantly lower than that in group B,after treatment( P〈0. 05). The DIC rate and death rate in group B and group C were significantly lower than those in group A( P〈0. 05). The DIC rate in group C was significantly lower than that in group B( P〈0. 05). Conclusion Low molecular weight heparin has a better clinical effects on sepsis which can improve coagulation and inflammation makes it worth for clinical application.
出处 《临床和实验医学杂志》 2016年第4期359-361,共3页 Journal of Clinical and Experimental Medicine
基金 中山市科技立项(编号:20122A115)
关键词 脓毒症 低分子肝素钙 肝素钠 Sepsis Low molecular weight heparin Heparin
  • 相关文献

参考文献11

  • 1Angus DC, van der Poll T. Severe sepsis and septic shock[J]. N Engl J Med, 2013,369(9) :840 -851.
  • 2Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012[J]. Intensive Care Med, 2013,39(2) :165 -228.
  • 3Kok M, Oei A, Karakus A, et al. Correlation between conventional and advanced hemodynamic parameters versus serum lactate in patients with severe sepsis[J]. Critical Care, 2014,18( Suppl 1 ):P173.
  • 4Ziegler T, Horstkotte J, Schwab C, et al. Angiopoietin 2 mediates mi- erovascular and hemodynamie alterations in sepsis [ J ]. J Clin Invest, 2013,123 (8) :34 - 36.
  • 5Opal SM, Dellinger RP, Vincent JL, et al. The next generation of sep- sis clinical trial designs: what is next after thedemise of recombinant hu- man activated protein C [ J ] ? Crit Care Med, 2014,42 (7) : 1714 - 1721.
  • 6Zarychanski R, Abou -Setta AM, Kanji S, et al. The efficacy and safety of heparin in patients with sepsis:a systematic reviewand meta- analysis[J]. Crit Care Med, 2015,43(3) :511 -518.
  • 7于爱真,王少雯,华子瑜.新生儿脓毒症临床诊断标准评估[J].实用儿科临床杂志,2011,26(22):1712-1715. 被引量:16
  • 8Levi M. The dual face of heparin in severe infection[ J]. Blood, 2014, 123(7) :947 -948.
  • 9Wildhagen KC, Garcfa de Frutos P, Reutelingsperger CP, et al. Non- anticoagulant heparin prevents histone - mediated cytotoxicity in vitro and improves survival in sepsis [ J ]. Blood, 2014,123 ( 7 ) : 1098 - 1101.
  • 10黄涛,关琦.低分子肝素治疗严重脓毒症的临床观察[J].中国医药导报,2010,7(14):58-59. 被引量:12

二级参考文献27

  • 1林洪远.从KyberSept和OPTIMIST研究失败看肝素治疗脓毒症的潜力[J].中国危重病急救医学,2007,19(3):134-137. 被引量:27
  • 2Bone RC,Balk RA,Cerra FB.et al.Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.The ACCP/SCCM consensus confetence committee.American college of chest physicians society of critical care medicine[J].Cheat,1992,101(6):1644-1655.
  • 3Mesters R,Helterbrand J,Utterback B G,et al.Prognonstic value of protein C concentrations in neutropenic patients at high risk of severe septic complications[J].Crit Care Med,2000,28:2209-2216.
  • 4Marshall JC,Cook DJ,Christou NV,et al.Multiple organ dysfunction score:a reliable descriptor of a complex clinical outcome[J].Crit Care Med,1995,23(10):1638-1652.
  • 5Comet AD,Smit EG,Beishuizen A,et al.The role of heparin and allied compounds in the treatment of sepsis[J].Thromb Haemost,2007,98(3):579-586.
  • 6Slofstra SH,van't Veer C,Buurman WA,et al.Low molecular weight heparin attenuates multiple organ failure in a murine model of dissemi-nated intravascular coagulation[J].Crit Care Med,2005,33:1365-1370.
  • 7邵肖梅,叶鸿瑶,丘小汕.实用新生儿学[M].4版.北京:人民卫生出版社,2011:807-808.
  • 8Thaver D, Zaidi AK. Burden of neonatal infections in developing coun- tries : A review of evidence from community - based studies [ J ]. Pediatr Infect Dis J,2009,25 ( suppl 1 ) : 3 - 9.
  • 9Waliullah MS, Islam MN, Siddika M,et al. Risk factors, clinical manifesta- tion and bacteriological profile of neonatal sepsis in a tertiary level pedia- tric hospital [ J ]. Mymensingh Med J,2009,18 ( suppl 1 ) :66 - 72.
  • 10Griffin MP, Lake DE, O'shea TM ,et al. Heart rate characteristics and cli- nical signs in neonatal sepsis[ J]. Pediatr Res ,2007,61 (2) :222 -227.

共引文献25

同被引文献142

引证文献18

二级引证文献157

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部